Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
eNq9mF1v2jAUhu/5FSgXu0tCoBS6JVQbazekVmO0aNNukEkOYObYqT8o9NfPIXSlU6J2BvcGiTh5z7HP8eM3Cc/XKamvgAvMaOQEXsOpA41Zguk8csa3l27XOe/VwiVaob3bOl7DC5pOPSZIiMjJR70pICq8n9dXn0E/D9zp1eohmy4hls/uUxIT7ysSi2uU5ffUwxXDST0FuWBJ5GRKbq/WQyG5zqJ3z/hvkaEYQn93ZX90OTnZvx76udgrVJUAfoXovFQUqJFmrDgHKvtIwpzxTUW+LSNtLEYgmOIxDJFcDDlb4QSS0hAzRAQYBZndJzfAVwRkHqRU3F/GqTASR0u0HsHdoDzpj3q0L9fSbbhBp3PS7LRO22edoGsUiu8tVXkV9CT8eBJ0GkGz2/KB+hs9b7ZxUyCIshTcJugfgucUXJxhglOVoqlh5YaMS0Qs1QyL/vO2sxSHw92LvZFgkRG08ZYiM10qxJEeBq7hYG8i+QxuucYV0Wv2jz5VhPj/mfV4BxNLGees6jNFZQVTLkemC9FnVMK6uqJmGJTrXS9iEMeTfWC0/AgYqinBsSnwNJIUCDkeDap593ao+IQEjLk9VvzANGH34vgM2q+5peyzLUZLRTOeBJPmWfc0aLeNt9gv3WAVp9OF4iwDX9MJi0OgM6AzdihudM+WSz127Bs169ZBsRgRqPBQriGXdJc+Wj5r+8DeHisGSkW/XNyaNs93BXxzs/1bKo2T6G/ZzaBt4yTQrfpS4sWmjrJJq9HunrVO3qE0+/BoziNDI16IWvHhipcTaCFlJt77/gIJVyC9lt6Mm54d56WLcoyF0aB+qrO9lwgrtqKwWQWkLaU+LU7f1xfYdDu/ZDoONdK753eGvTSG5AoOqENBfmt8HlwcH/lPLtpa2sNn4LEXZut4kcSM2vJaalqqeNgho+tKL7mGw7fZDFd80Knsy9AvPib1aqGff0jq1f4ATsUqqw==
8FKdXtNg6FbwPSyh
